Spero Therapeutics (SPRO) Stock Forecast, Price Target & Predictions
SPRO Stock Forecast
Spero Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
SPRO Analyst Ratings
According to 2 Wall Street analysts, Spero Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SPRO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | Cowen & Co. | - | Buy | Upgrade |
| Sep 22, 2022 | Evercore ISI | - | Outperform | Upgrade |
Spero Therapeutics's last stock rating was published by Cowen & Co. on Aug 06, 2024. The company Upgrade its SPRO rating from "null" to "Buy".
Spero Therapeutics Financial Forecast
Spero Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $71.83M | $25.47M | $2.72M | $740.00K | $46.30M | $1.08M | $896.00K | $247.00K | $2.74M | $3.06M | $5.15M | $7.30M | $1.91M | $4.00M | $1.73M | $1.70M | $3.63M | $4.64M | $2.16M | $7.72M | $1.15M |
| Avg Forecast | $25.00M | $11.00M | $10.00M | $10.00M | $5.10M | $5.00M | $4.90M | $21.53M | $18.63M | $14.97M | $1.08M | $1.27M | $866.67K | $5.42M | $1.43M | $1.93M | $4.95M | $4.47M | $4.53M | $3.75M | $3.67M | $3.01M | $3.31M | $3.44M | $3.91M | $2.45M | $6.31M | $2.83M | $1.87M |
| High Forecast | $25.00M | $11.00M | $10.00M | $10.00M | $5.10M | $5.00M | $4.90M | $21.53M | $18.63M | $14.97M | $1.08M | $1.27M | $866.67K | $5.42M | $1.43M | $1.93M | $4.95M | $4.47M | $4.53M | $3.75M | $3.67M | $3.01M | $3.31M | $3.44M | $3.91M | $2.45M | $6.31M | $2.83M | $2.24M |
| Low Forecast | $25.00M | $11.00M | $10.00M | $10.00M | $5.10M | $5.00M | $4.90M | $21.53M | $18.63M | $14.97M | $1.08M | $1.27M | $866.67K | $5.42M | $1.43M | $1.93M | $4.95M | $4.47M | $4.53M | $3.75M | $3.67M | $3.01M | $3.31M | $3.44M | $3.91M | $2.45M | $6.31M | $2.83M | $1.50M |
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | 3.85% | 1.70% | 2.51% | 0.58% | 53.42% | 0.20% | 0.63% | 0.13% | 0.55% | 0.69% | 1.14% | 1.95% | 0.52% | 1.33% | 0.52% | 0.49% | 0.93% | 1.89% | 0.34% | 2.73% | 0.62% |
Spero Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $21.53M, with a low forecast of $21.53M, and a high forecast of $21.53M. SPRO's average Quarter revenue forecast represents a -70.02% decrease compared to the company's last Quarter revenue of $71.83M (Dec 23).
Spero Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | $48.87M | $-1.93M | $-12.89M | $-13.15M | $25.79M | $-11.54M | $-13.84M | $-29.96M | $-27.11M | $-22.37M | $-18.42M | $-19.26M | $-18.39M | $-18.75M | $-17.31M | $-23.07M | $-25.10M | $-17.23M | $-12.96M | $-4.89M | $-10.55M |
| Avg Forecast | $-15.91M | $-7.00M | $-6.36M | $-6.36M | $-3.25M | $-3.18M | $-3.12M | $-13.70M | $-11.86M | $-9.52M | $-689.42K | $-806.09K | $-551.54K | $-3.45M | $-912.16K | $-1.23M | $-3.15M | $-2.84M | $-2.88M | $-18.66M | $-2.34M | $-1.91M | $-2.11M | $-23.62M | $-2.49M | $-1.56M | $-4.02M | $-7.16M | $-14.59M |
| High Forecast | $-15.91M | $-7.00M | $-6.36M | $-6.36M | $-3.25M | $-3.18M | $-3.12M | $-13.70M | $-11.86M | $-9.52M | $-689.42K | $-806.09K | $-551.54K | $-3.45M | $-912.16K | $-1.23M | $-3.15M | $-2.84M | $-2.88M | $-14.93M | $-2.34M | $-1.91M | $-2.11M | $-18.90M | $-2.49M | $-1.56M | $-4.02M | $-5.73M | $-11.67M |
| Low Forecast | $-15.91M | $-7.00M | $-6.36M | $-6.36M | $-3.25M | $-3.18M | $-3.12M | $-13.70M | $-11.86M | $-9.52M | $-689.42K | $-806.09K | $-551.54K | $-3.45M | $-912.16K | $-1.23M | $-3.15M | $-2.84M | $-2.88M | $-22.39M | $-2.34M | $-1.91M | $-2.11M | $-28.35M | $-2.49M | $-1.56M | $-4.02M | $-8.60M | $-17.51M |
| Surprise % | - | - | - | - | - | - | - | - | -4.12% | 0.20% | 18.70% | 16.32% | -46.76% | 3.35% | 15.17% | 24.46% | 8.61% | 7.87% | 6.40% | 1.03% | 7.87% | 9.80% | 8.21% | 0.98% | 10.08% | 11.04% | 3.23% | 0.68% | 0.72% |
1 analysts predict SPRO's average Quarter EBITDA for Mar 24 to be $-13.70M, with a high of $-13.70M and a low of $-13.70M. This is -128.04% lower than Spero Therapeutics's previous annual EBITDA (Dec 23) of $48.87M.
Spero Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| Net Income | - | - | - | - | - | - | - | - | $51.19M | $-3.21M | $-11.91M | $-12.30M | $26.77M | $-11.52M | $-31.28M | $-35.45M | $-31.18M | $-22.52M | $-18.57M | $-19.42M | $-18.59M | $-18.94M | $-17.50M | $-23.26M | $-24.99M | $-17.72M | $-13.15M | $-5.07M | $-10.64M |
| Avg Forecast | $-18.08M | $-25.09M | $-26.17M | $-26.44M | $-27.88M | $-26.80M | $-20.50M | $-2.34M | $-5.40M | $-1.62M | $-18.53M | $-17.99M | $-19.06M | $-16.37M | $-50.00M | $-50.18M | $-40.33M | $-35.79M | $-40.47M | $-18.82M | $-39.50M | $-47.16M | $-60.43M | $-23.82M | $-57.91M | $-45.32M | $-34.53M | $-7.43M | $-14.72M |
| High Forecast | $-18.08M | $-25.09M | $-26.17M | $-26.44M | $-27.88M | $-21.67M | $-20.50M | $-2.34M | $-1.80M | $-1.62M | $-18.53M | $-17.99M | $-19.06M | $-16.37M | $-50.00M | $-50.18M | $-40.33M | $-35.79M | $-40.47M | $-15.05M | $-39.50M | $-47.16M | $-60.43M | $-19.05M | $-57.91M | $-45.32M | $-34.53M | $-5.95M | $-11.78M |
| Low Forecast | $-18.08M | $-25.09M | $-26.17M | $-26.44M | $-27.88M | $-31.36M | $-20.50M | $-2.34M | $-8.69M | $-1.62M | $-18.53M | $-17.99M | $-19.06M | $-16.37M | $-50.00M | $-50.18M | $-40.33M | $-35.79M | $-40.47M | $-22.58M | $-39.50M | $-47.16M | $-60.43M | $-28.58M | $-57.91M | $-45.32M | $-34.53M | $-8.92M | $-17.67M |
| Surprise % | - | - | - | - | - | - | - | - | -9.49% | 1.98% | 0.64% | 0.68% | -1.40% | 0.70% | 0.63% | 0.71% | 0.77% | 0.63% | 0.46% | 1.03% | 0.47% | 0.40% | 0.29% | 0.98% | 0.43% | 0.39% | 0.38% | 0.68% | 0.72% |
Spero Therapeutics's average Quarter net income forecast for Mar 24 is $-2.34M, with a range of $-2.34M to $-2.34M. SPRO's average Quarter net income forecast represents a -104.57% decrease compared to the company's last Quarter net income of $51.19M (Dec 23).
Spero Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| SG&A | - | - | - | - | - | - | - | - | $6.43M | $5.71M | $6.10M | $7.32M | $6.50M | $6.63M | $8.05M | $15.30M | $13.02M | $11.15M | $9.23M | $8.30M | $7.50M | $5.31M | $4.55M | $4.09M | $3.79M | $4.13M | $3.78M | $3.89M | $3.04M |
| Avg Forecast | $44.42M | $19.55M | $17.77M | $17.77M | $9.06M | $8.88M | $8.71M | $38.26M | $33.11M | $26.59M | $1.92M | $2.25M | $1.54M | $9.62M | $2.55M | $3.42M | $8.80M | $7.94M | $8.04M | $6.66M | $6.52M | $5.34M | $5.89M | $6.12M | $6.95M | $4.36M | $11.22M | $5.02M | $3.32M |
| High Forecast | $44.42M | $19.55M | $17.77M | $17.77M | $9.06M | $8.88M | $8.71M | $38.26M | $33.11M | $26.59M | $1.92M | $2.25M | $1.54M | $9.62M | $2.55M | $3.42M | $8.80M | $7.94M | $8.04M | $6.66M | $6.52M | $5.34M | $5.89M | $6.12M | $6.95M | $4.36M | $11.22M | $5.02M | $3.99M |
| Low Forecast | $44.42M | $19.55M | $17.77M | $17.77M | $9.06M | $8.88M | $8.71M | $38.26M | $33.11M | $26.59M | $1.92M | $2.25M | $1.54M | $9.62M | $2.55M | $3.42M | $8.80M | $7.94M | $8.04M | $6.66M | $6.52M | $5.34M | $5.89M | $6.12M | $6.95M | $4.36M | $11.22M | $5.02M | $2.66M |
| Surprise % | - | - | - | - | - | - | - | - | 0.19% | 0.21% | 3.17% | 3.25% | 4.22% | 0.69% | 3.16% | 4.47% | 1.48% | 1.41% | 1.15% | 1.25% | 1.15% | 0.99% | 0.77% | 0.67% | 0.54% | 0.95% | 0.34% | 0.77% | 0.92% |
Spero Therapeutics's average Quarter SG&A projection for Mar 24 is $38.26M, based on 1 Wall Street analysts, with a range of $38.26M to $38.26M. The forecast indicates a 494.79% rise compared to SPRO last annual SG&A of $6.43M (Dec 23).
Spero Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| EPS | - | - | - | - | - | - | - | - | $0.96 | $-0.06 | $-0.00 | $-0.23 | $-0.98 | $-0.32 | $-0.95 | $-1.09 | $-0.97 | $-0.70 | $-0.63 | $-0.66 | $-0.68 | $-0.86 | $-0.85 | $-1.22 | $-1.32 | $-0.95 | $-0.74 | $-0.29 | $-0.74 |
| Avg Forecast | $-0.34 | $-0.47 | $-0.48 | $-0.49 | $-0.52 | $-0.50 | $-0.38 | $-0.04 | $-0.10 | $-0.03 | $-0.34 | $-0.33 | $-0.35 | $-0.30 | $-0.93 | $-0.93 | $-0.75 | $-0.66 | $-0.75 | $-0.63 | $-0.73 | $-0.87 | $-1.12 | $-1.24 | $-1.07 | $-0.84 | $-0.64 | $-0.77 | $-1.66 |
| High Forecast | $-0.34 | $-0.47 | $-0.48 | $-0.49 | $-0.52 | $-0.40 | $-0.38 | $-0.04 | $-0.03 | $-0.03 | $-0.34 | $-0.33 | $-0.35 | $-0.30 | $-0.93 | $-0.93 | $-0.75 | $-0.66 | $-0.75 | $-0.63 | $-0.73 | $-0.87 | $-1.12 | $-1.24 | $-1.07 | $-0.84 | $-0.64 | $-0.77 | $-1.33 |
| Low Forecast | $-0.34 | $-0.47 | $-0.48 | $-0.49 | $-0.52 | $-0.58 | $-0.38 | $-0.04 | $-0.16 | $-0.03 | $-0.34 | $-0.33 | $-0.35 | $-0.30 | $-0.93 | $-0.93 | $-0.75 | $-0.66 | $-0.75 | $-0.63 | $-0.73 | $-0.87 | $-1.12 | $-1.24 | $-1.07 | $-0.84 | $-0.64 | $-0.77 | $-1.99 |
| Surprise % | - | - | - | - | - | - | - | - | -9.60% | 2.03% | 0.00% | 0.69% | 2.77% | 1.05% | 1.03% | 1.17% | 1.30% | 1.06% | 0.84% | 1.05% | 0.93% | 0.98% | 0.76% | 0.98% | 1.23% | 1.13% | 1.16% | 0.38% | 0.45% |
According to 1 Wall Street analysts, Spero Therapeutics's projected average Quarter EPS for Mar 24 is $-0.04, with a low estimate of $-0.04 and a high estimate of $-0.04. This represents a -104.51% decrease compared to SPRO previous annual EPS of $0.96 (Dec 23).
Spero Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| NUVB | Nuvation Bio | $3.05 | $7.00 | 129.51% | Buy |
| NXTC | NextCure | $1.40 | $3.00 | 114.29% | Buy |
| TIL | Instil Bio | $84.52 | $17.67 | -79.09% | Hold |
SPRO Forecast FAQ
Is Spero Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Spero Therapeutics (SPRO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of SPRO's total ratings.
What are Spero Therapeutics's analysts' financial forecasts?
Spero Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $36.53M (high $36.53M, low $36.53M), average EBITDA is $-23.249M (high $-23.249M, low $-23.249M), average net income is $-77.52M (high $-72.388M, low $-82.081M), average SG&A $64.92M (high $64.92M, low $64.92M), and average EPS is $-1.437 (high $-1.342, low $-1.521). SPRO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $56M (high $56M, low $56M), average EBITDA is $-35.638M (high $-35.638M, low $-35.638M), average net income is $-95.775M (high $-95.775M, low $-95.775M), average SG&A $99.51M (high $99.51M, low $99.51M), and average EPS is $-1.775 (high $-1.775, low $-1.775).
Did the SPRO's actual financial results beat the analysts' financial forecasts?
Based on Spero Therapeutics's last annual report (Dec 2023), the company's revenue was $96.74M, beating the average analysts forecast of $35.95M by 169.08%. Apple's EBITDA was $20.11M, missing the average prediction of $-22.878M by -187.89%. The company's net income was $22.81M, missing the average estimation of $-43.526M by -152.40%. Apple's SG&A was $25.55M, missing the average forecast of $63.88M by -60.00%. Lastly, the company's EPS was $0.43, missing the average prediction of $-0.807 by -153.31%. In terms of the last quarterly report (Dec 2023), Spero Therapeutics's revenue was $71.83M, beating the average analysts' forecast of $18.63M by 285.48%. The company's EBITDA was $48.87M, missing the average prediction of $-11.858M by -512.16%. Spero Therapeutics's net income was $51.19M, missing the average estimation of $-5.396M by -1048.74%. The company's SG&A was $6.43M, missing the average forecast of $33.11M by -80.57%. Lastly, the company's EPS was $0.96, missing the average prediction of $-0.1 by -1060.00%